Real-world second-line treatment pattern for unresectable or advanced hepatic carcinoma in China: a retrospective database study.

ABSTRACT:

Background

In recent years, the emerging new drugs in the Chinese market diversified the choice of systemic treatment, especially second-line (2L), for unresectable or advanced hepatic carcinoma (HC) patients, and their inclusion into the National Reimbursement Drug List (NRDL) further changed the clinical practice. The objective of this study was to describe the 2L treatment pattern among Chinese unresectable or advanced HC patients in a real-world setting.

Methods

All adult unresectable or advanced HC patients receiving 2L treatment were retrospectively identified from Tianjin Healthcare and Medical Big Data Platform, a regional electronic health record database in Tianjin, China. Patients were observed between 2018 and 2021. A descriptive analysis was conducted for study

SUBMITTER: Leng J 

PROVIDER: S-EPMC12432968 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature